echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > New anti-inflammatory drugs! Yukbi bimekizumab medium to severe plaque type psoriasis Phase III: better than Novartis Cosentyx (good) !

    New anti-inflammatory drugs! Yukbi bimekizumab medium to severe plaque type psoriasis Phase III: better than Novartis Cosentyx (good) !

    • Last Update: 2020-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    25 July 2020 // UCB recently published positive results for the 3b BE RADIANT Study (NCT03536884).
    the study was conducted in adult patients with moderate-to-severe plaque-type psoriasis, and directly compared the new anti-inflammatory drug IL-17A/IL-17F inhibitor bimekizumab with Novartis IL-17A inhibitor Cosentyx (Chinese commodity name: good, generic name: secukinumab, skuchiyu singantigen, commonly known as "Sukin monovirus").
    noteworthy, this study is the first to compare head-to-head studies of anti-IL-17 inhibitors, and the first to demonstrate that bimekizumab is superior to Cosentyx in the complete removal of skin loss in weeks 16 and 48.
    results confirm the speed, depth, and persistence of mitigation in the three previous Phase III studies, and emphasize the importance of selective inhibition of IL-17F and IL-17A.
    bimekizumab is a unique molecule with a dual action mechanism, a new type of human-derived monoclonal IgG1 antibody that can effectively and selectively neutralize IL-17A and IL-17F, which are the two key cytokines that drive the inflammatory process.
    IL-17A and IL-17F have similar pro-inflammatory functions and independently work with other inflammatory media to drive chronic inflammation and damage in multiple tissues.
    bimekizumab's unique IL-17A/IL-17F double inhibition may provide a new targeted therapy for the treatment of immune-mediated inflammatory diseases.
    preclinical studies in disease-related cells have shown that inhibiting IL-17F while inhibiting IL-17A reduces skin and arthritis and pathological bone formation to a greater extent than the individual inhibition of IL-17A.
    , bimekizumab is currently in Phase III clinical development for the treatment of a variety of inflammatory diseases, including plaque-type psoriasis, psoriasis arthritis, mid-axis spinal arthritis, and septic sweat aditus.
    BE-RADIANT is a randomized, multi-center, double-blind, positive-control, parallel group study designed to assess the effectiveness and safety of bimekizumab and Cosentyx in adult patients with moderate to severe chronic plaque psoriasis.
    the study included 743 patients with pre-screening psoriasis for at least 6 months, baseline PASI score of 12, body surface area (BSA) affected by psoriasis , and IGA score of 3.
    the study included a 48-week double-blind treatment period (44 weeks of final dose) and a 96-week open label extension (OLE). The primary endpoint of the
    was the complete removal rate of skin loss at week 16 of treatment (with the PASI 100 evaluation, which defined the area and severity of psoriasis index (PASI) score improved by 100 per cent over the baseline level).
    data show that the study reached its main end: at the 16th week of treatment, bimekizumab outperformed Cosentyx in the complete removal of skin damage.
    in addition, the study reached all secondary endpoints and was statistically significant.
    bimekizumab is better than Cosentyx on a monthly basis (Q4W) and once a month (Q8W) in terms of the complete removal of PASI 75 and week 48 during the fourth week of treatment.
    ongoing data assessments indicate that the safety of bimekizumab is consistent with earlier clinical studies.
    bimekizumab has a robust Psoriad Phase 3 clinical development project. The detailed results of
    2 Phase III studies BE VIVID and BE READY were first presented at the American Society of Dermatology (AAD) 2020 Annual Meeting in June 2020, and the results of THE BE SURE study will be published this year.
    full results from the BE RADIANT study will be published in due course. In the BE VIVID and BE READY studies presented at the
    AAD 2020, patients treated with bimekizumab showed better removal of the skin loss during the 16th week of treatment compared to patients treated with placebo or Johnson IL-12/IL-23 inhibitor Stelara (Chinese commodity name: Sidano ®, generic name: ustekinumab, ustekzumab). "Psoriasis places a heavy burden on patients and often causes pain, discomfort and stigma," said Emmanuel Caeymaex, executive vice president of
    's Uber Immune Solutions and head of u.S.
    patients may not get the skin loss they want completely removed, or may not even realize that this is possible.
    healthcare providers may also feel forced to balance fast and effective treatments with treatments that have shown lasting efficacy.
    BE RADIANT research results show that bimekizumab has the potential to improve the standard of treatment of patients and their dermatologists.
    UCB is proud to link leading science to the needs of unmet patients and to develop bimekizumab.
    our ambition is to provide a transformative treatment experience for psoriasis patients.
    " () Original source: Bimekizumab Superior to Cosentyx® in Achieving Complete Psoriasis Skin Clearance.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.